SAN DIEGO , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase inhibitors Findings support development of tipifarnib in certain bone marrow cancers
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with RAS wild-type achieved stable disease or better – – Preliminary data presented
SAN DIEGO , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017 , from 8:30 a.m.
Management to host webcast and conference call today at 4:30 p.m. ET SAN DIEGO , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2017
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been
SAN DIEGO , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2017 financial results after the close of U.S.
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patients Menin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO , Oct. 28, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCC Tipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one year Registration-enabling study of tipifarnib in HRAS mutant HNSCC planned for 2018 SAN DIEGO , Oct.
SAN DIEGO , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
